Recovery & Tissue Repair Preliminary evidence

BPC-157 + TB-500

BPC-157 and TB-500 (Thymosin β-4 fragment) combination

Also known as: BPC-157/TB-500 blend, BPC-TB stack

In plain language

This is a blend of two research peptides, BPC-157 and TB-500, often marketed together for tissue repair. Each peptide on its own has only animal-level evidence, and the specific combination has not been tested in controlled human trials. Claims about the blend are not backed by human data.

What it is explored for

This blend pairs two popular recovery peptides on the idea that they support healing through different pathways, which is why it attracts so much interest. To be honest, each peptide has only animal-level evidence, and the specific combination has never been tested in controlled human trials. Here is where reported interest and anecdotal use are highest.

  • Tendon, ligament, and muscle recovery
  • Soft-tissue and wound healing
  • Gut and digestive lining interest
  • Post-injury recovery research
  • Calming inflammation

These are areas of active interest and reported use, not proven outcomes. This peptide carries a preliminary evidence rating, see the evidence summary below for how strong the science actually is.

How it works

The rationale for combining these peptides is that they are thought to support healing through different pathways. This rationale comes from separate animal studies of each peptide, not from studies of the blend.

  • BPC-157 component. In animal models, BPC-157 is associated with angiogenesis, collagen organization, and gut and tendon healing.
  • TB-500 component. TB-500 is a fragment of Thymosin β-4 reported in animals to influence cell migration and actin regulation during repair.
  • Proposed complementary action. Marketers suggest the two cover different parts of the healing process, but no study has tested whether combining them adds benefit.

All mechanisms come from separate animal and cell studies of the individual peptides. There is no controlled evidence that the combination works in humans.

Evidence summary

Evidence for the blend specifically is essentially absent. Each component has rodent and in-vitro data but no well-controlled human trials. Combining them is a marketing and anecdote-driven practice rather than an evidence-based protocol.

Reported safety & side effects

Human safety of either peptide is not established, and the safety of using them together is even less studied. Combining unapproved research compounds can compound unknown risks.

Human safety dataNot established for either peptide or the blend
Combination riskUnknown; no interaction studies
ContraindicationsUnknown; active or suspected cancer is a common research exclusion

Frequently asked

Is the BPC-157 + TB-500 blend proven for injury recovery?

No. There are no controlled human trials of the blend. The supporting data are animal studies of each peptide separately.

Why are they sold together?

They are marketed as a "healing stack" on the theory that they act through different pathways. That theory has not been tested in people.